Osicent 80 mg is an oral targeted anticancer medication containing Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). It is specifically developed for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) harboring the EGFR T790M mutation, whose disease has progressed during or after prior EGFR-TKI therapy. Osicent 80 mg offers a precision-based treatment approach by selectively targeting resistant EGFR mutations while minimizing effects on normal cells.

Indications

Osicent 80 mg is indicated for the treatment of adult patients with:

• Metastatic EGFR T790M mutation-positive non-small cell lung cancer (NSCLC)

• Disease progression on or after prior EGFR tyrosine kinase inhibitor (TKI) therapy
  Mutation status should be confirmed using an FDA-approved diagnostic test prior to initiating therapy.

Therapeutic Class

Cytotoxic Chemotherapy / Targeted Cancer Therapy (EGFR Tyrosine Kinase Inhibitor)

Pharmacology

Osicent 80 mg acts as a selective, irreversible inhibitor of mutant EGFR forms, including:

• EGFR T790M

• EGFR L858R

• EGFR exon 19 deletion

These mutations are commonly associated with resistance to first- and second-generation EGFR-TKIs. As a third-generation inhibitor, Osicent 80 mg demonstrates high activity against the T790M “gatekeeper” mutation, which enhances ATP binding to EGFR and contributes to poor prognosis in advanced disease. Importantly, Osicent has reduced activity against wild-type EGFR, helping to lower off-target toxicity and improve tolerability.

Mode of Action

Osicent 80 mg binds irreversibly to mutant EGFR tyrosine kinase domains, blocking downstream signaling pathways responsible for tumor cell proliferation and survival. This targeted inhibition results in growth arrest and apoptosis of EGFR-mutant cancer cells while sparing normal tissues.

Dosage & Administration

• Recommended Dose: 80 mg orally once daily

• Continue treatment until disease progression or unacceptable toxicity

• Can be taken with or without food

• If a dose is missed, skip the missed dose and resume the regular dosing schedule

Administration for Patients with Swallowing Difficulty:

• Disperse the tablet in 60 ml of non-carbonated water

• Stir until broken into small pieces (do not crush or heat)

• Swallow immediately and rinse the container with additional water

• For nasogastric tube use, follow recommended dispersion and flushing instructions

Drug Interactions

• Strong CYP3A4 Inducers: May reduce drug exposure

  • If unavoidable, increase dose to 160 mg once daily

  • Resume 80 mg dose 3 weeks after discontinuation of inducer

Side Effects

Common or clinically significant adverse reactions include:

• Interstitial lung disease or pneumonitis

• QTc interval prolongation

• Cardiomyopathy

• Keratitis

Patients should undergo regular cardiac and pulmonary monitoring during therapy.

Pregnancy, Lactation & Fertility

• Pregnancy: Osicent 80 mg may cause fetal harm and is not recommended during pregnancy

• Lactation: Breastfeeding should be discontinued during treatment

• Fertility: Animal studies suggest potential impairment of male and female fertility

Effective contraception is recommended for women of childbearing potential.

Storage Conditions

Store at 20°C to 25°C in a dry place. Dispose of unused or expired medicine safely. Keep out of reach of children.